Objective: To investigate the feasibility, efficacy and safety of ultrasound-guided high-intensity focused ultrasound (HIFU) ablation for treating the broad ligament uterine fibroid (BLUF).
Methods: A total of 236 patients with symptomatic uterine fibroids were enrolled and treated with JC-200 extracorporeal ultrasound-guided HIFU under conscious sedation between January 2017 and December 2018. Of them, data of 12 patients with 13 broad ligament fibroids were retrospectively analyzed. The patients' mean age was 38.6 ± 6.3 years. The focused ultrasound target was deployed and moved from the deeper layer to the superficial layer of BLUFs. All patients underwent contrast-enhanced MRI (CE-MRI) before, immediate post-operation, and six months after the HIFU ablation procedure. The fibroid size, non-perfusion volume (NPV) ratio, the reduction of fibroid volumes, adverse events, symptom changes, and abnormal MRI findings associated with the HIFU treatment were analyzed.
Results: Ultrasound-guided HIFU ablation in the twelve patients was technically successful with one session treatment. The mean longest diameter of BLUFs was 6.2 ± 2.3 cm. The mean NPV ratio of fibroids was 84.08%± 9.4%. After HIFU ablation, lower abdominal pain occurred in 7 cases, sacrococcygeal pain in 3 cases, and mild skin pain in 6 cases. There were no severe adverse events and complications associated with the treatment. At 6 months post-treatment follow-up, the mean fibroid volume decreased by 56.2%± 9.0% ( < 0.05), and the symptoms related to broad ligament fibroids were improved or disappeared.
Conclusions: Ultrasound-guided high-intensity focused ultrasound ablation is feasible, effective, and safe for treating broad ligament fibroids.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/02656736.2021.1921287 | DOI Listing |
To establish a multivariate linear regression model for predicting the difficulty of high-intensity focused ultrasound (HIFU) ablation of uterine fibroids based on multi-sequence magnetic resonance imaging radiomics features. A retrospective analysis was conducted on 218 patients with uterine fibroids who underwent HIFU treatment, including 178 cases from Yongchuan Hospital of Chongqing Medical University and 40 cases from the Second Affiliated Hospital of Chongqing Medical University (external validation set). Radiomics features were extracted and selected from magnetic resonance images, and potentially related imaging features were collected.
View Article and Find Full Text PDFTransl Oncol
January 2025
Department of Urology, Cedars Sinai Medical Center, 8635 W. Third St, 1070, Los Angeles, CA 90048, United States. Electronic address:
Treatment options for localized prostate cancer have been expanded by FDA-approval of High-Intensity Focused Ultrasound (HIFU). Prostate cancer typically has few tumor-infiltrating lymphocytes, which are crucial for antitumor immunity. This study investigated the use of HIFU to increase lymphocyte infiltration into the tumor and enhance antitumor immunity.
View Article and Find Full Text PDFLife (Basel)
December 2024
Operative Care Line, Urology Section, Michael E. DeBakey Veteran Affairs Medical Center, Houston, TX 77030, USA.
High-Intensity Focused Ultrasound (HIFU) provides comparable oncologic, erectile, and urinary outcomes to standard-of-care options for localized prostate cancer. This study reports the largest United States series of HIFU in veterans for both primary and salvage therapies. We retrospectively analyzed the outcomes of 43 veterans treated at the Michael E.
View Article and Find Full Text PDFCurr Oncol
December 2024
Nuclear Medicine, Alma Mater Studiorum, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy.
Focal therapy offers a promising approach for treating localized prostate cancer (PC) with minimal invasiveness and potential cost benefits. High-intensity focused ultrasound (HIFU) and brachytherapy (BT) are among these options but lack long-term efficacy data. Patient follow-ups typically use biopsies and multiparametric MRI (mpMRI), which often miss recurrences.
View Article and Find Full Text PDFHPB (Oxford)
January 2025
Department of Surgery, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong, China; Department of Surgery, University of Hong Kong, 102 Pokfulam Road, Hong Kong, China.
Background: The recommended first-line treatment for respectable hepatocellular carcinoma (HCC) is surgical resection, but local ablation has gained popularity as a safe alternative. This study aims to compare the effectiveness of radiofrequency ablation (RFA), microwave ablation (MWA) and high-intensity focused ultrasound (HIFU) as first-line treatments for HCC.
Methods: In this single-centre retrospective study, 352 patients receiving RFA, MWA, or HIFU as first-line treatment for HCC were included.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!